HomeWorld NewsUS NewsAbbVie's rheumatoid arthritis drug succeeds in late-stage study

AbbVie’s rheumatoid arthritis drug succeeds in late-stage study

AbbVie's rheumatoid arthritis drug succeeds in late-stage study

AbbVie said on Tuesday its experimental drug met the main goal of halting progression of moderate-to-severe rheumatoid arthritis in a late-stage trial.

The drug, upadacitinib, was tested as a monotherapy in patients who have not been treated with chemotherapy agent methotrexate.

Upadacitinib, which belongs to a class of drugs known as JAK inhibitors, also helped improve symptoms of the disease such as swollen joint counts, the company said, adding it plans to submit a U.S. marketing application in the second half of 2018.

AbbVie, whose drug Humira is the market-leading treatment for rheumatoid arthritis, is among drugmakers developing JAK inhibitors, which work by blocking inflammation-causing enzymes known as Janus kinases.

Last week, the Food and Drug Administration approved lower doses of another JAK inhibitor developer by Eli Lilly and Incyte, but gave it a label that analysts said could restrict its potential for use in a larger population.

More Related Articles

Sign up to receive awesome contents in your inbox, everyday in the morning.

We don’t spam! Read our privacy policy for more info.


Please enter your comment!
Please enter your name here

We use cookies to ensure that we give you the best experience on our website.